학술논문
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Document Type
article
Author
Sibylle Loibl; Chiun-Sheng Huang; Max S. Mano; Eleftherios P. Mamounas; Charles E. Geyer; Michael Untch; Jean-Christophe Thery; Ingo Schwaner; Steven Limentani; Niklas Loman; Kristina Lübbe; Jenny C. Chang; Thomas Hatschek; David Tesarowski; Chunyan Song; Sanne Lysbet de Haas; Thomas Boulet; Chiara Lambertini; Norman Wolmark
Source
npj Breast Cancer, Vol 8, Iss 1, Pp 1-6 (2022)
Subject
Language
English
ISSN
2374-4677
Abstract
Abstract Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant treatment. In the 70/845 (8.3%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.